|Calculated MW||Calculated MW of 12.8 kDa with no tag. The predicted N-terminus is Asn49. DTT-reduced protein migrates as 16 kDa due to glycosylation.|
|Other Names||IL-15, IL15, Interleukin-15|
|Source||HEK 293 cells|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in sterile deionized water to a concentration of 100 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in 20 mM Tris, 100 mM NaCl, pH 8.0. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Interleukin 15, also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus (es). This cytokine induces cell proliferation of natural killer cells; cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x (L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health
Grabstein K.H.,et al.Science 264:965-968(1994).
Krause H.,et al.Cytokine 8:667-674(1996).
Meazza R.,et al.Oncogene 12:2187-2192(1996).
Tagaya Y.,et al.Proc. Natl. Acad. Sci. U.S.A. 94:14444-14449(1997).
Meazza R.,et al.Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.